NASDAQ:GRI GRI Bio (GRI) Stock Price, News & Analysis → $1,500 to $9,400 in one month? (A.I. Trade List) (From Prosper Trading Academy) (Ad) Free GRI Stock Alerts 0.43 -0.03 (-5.53%) (As of 03:08 PM ET) Add Compare Share Share Today's Range0.41▼0.4450-Day Range0.39▼0.8052-Week Range0.38▼48.93Volume170,077 shsAverage Volume565,704 shsMarket Capitalization$1.62 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial Media Get GRI Bio alerts: Email Address Ad Prosper Trading Academy$1,500 to $9,400 in one month? (A.I. Trade List)This brand new A.I. Machine finds stocks and options trades which have had nearly PERFECT WIN RATES and gains as high as 1729%*Click here to reserve your free seat About GRI Bio Stock (NASDAQ:GRI)GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.Read More GRI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GRI Stock News HeadlinesMay 23 at 1:47 PM | finance.yahoo.comGRI Bio (NASDAQ: GRI) Participates in Virtual Investor CEO ConnectMay 22 at 9:15 AM | globenewswire.comGRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) ProgramsMay 21 at 8:35 AM | globenewswire.comGRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)May 20 at 8:58 AM | finance.yahoo.comGRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)May 20 at 8:45 AM | globenewswire.comGRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)May 16, 2024 | americanbankingnews.comGRI Bio (NASDAQ:GRI) Shares Down 1.2% May 15, 2024 | washingtonpost.comZiopharm: Q1 Earnings SnapshotMay 14, 2024 | finance.yahoo.comGRI Bio to Present at Alliance Global Partner’s 2024 Healthcare Company ShowcaseMay 14, 2024 | globenewswire.comGRI Bio to Present at Alliance Global Partner's 2024 Healthcare Company ShowcaseMay 13, 2024 | msn.comGRI Stock Earnings: GRI Bio Reported Results for Q1 2024May 13, 2024 | globenewswire.comGRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 13, 2024 | americanbankingnews.comGRI Bio (NASDAQ:GRI) Releases Earnings ResultsMay 2, 2024 | msn.comBabraham-based Harness Therapeutics appoints Meenu Chhabra Karson as board chairApril 29, 2024 | globenewswire.comGRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on AutoimmunityApril 25, 2024 | globenewswire.comGRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment WebinarApril 18, 2024 | finanznachrichten.deGRI Bio, Inc.: GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea PatentApril 16, 2024 | globenewswire.comGRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea PatentApril 8, 2024 | globenewswire.comGRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International ConferenceApril 1, 2024 | globenewswire.comGRI Bio Reports Full Year 2023 Financial Results and Provides Corporate UpdateMarch 28, 2024 | globenewswire.comGRI Bio to Present at the MedInvest Biotech & Pharma Investor ConferenceMarch 14, 2024 | finanznachrichten.deGRI Bio, Inc.: GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell ModulatorsMarch 14, 2024 | finance.yahoo.comGRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell ModulatorsMarch 14, 2024 | globenewswire.comGRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell ModulatorsMarch 4, 2024 | finanznachrichten.deGRI Bio, Inc.: GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United KingdomMarch 4, 2024 | globenewswire.comGRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United KingdomSee More Headlines Receive GRI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GRI Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/10/2024Today5/23/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GRI CUSIPN/A CIK1824293 Webwww.vallon-pharma.com Phone267-607-8255FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,040,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-548.12% Return on Assets-290.50% Debt Debt-to-Equity RatioN/A Current Ratio2.64 Quick Ratio2.64 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value0.74 per share Price / Book0.57Miscellaneous Outstanding Shares3,770,000Free Float3,662,000Market Cap$1.58 million OptionableNot Optionable Beta-1.55 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. W. Marc Hertz Ph.D. (Age 53)Co-Founder, CEO, President & Director Comp: $842.01kMs. Leanne M. Kelly (Age 47)CFO & Corporate Secretary Comp: $550.93kDr. Vipin Kumar Chaturvedi Ph.D. (Age 64)Co-Founder & Chief Scientific Officer Dr. Albert Agro Ph.d. (Age 59)Chief Medical Officer Key CompetitorsBiodexa PharmaceuticalsNASDAQ:BDRXDermata TherapeuticsNASDAQ:DRMAPaxMedicaNASDAQ:PXMDPainReformNASDAQ:PRFXAllarity TherapeuticsNASDAQ:ALLRView All Competitors GRI Stock Analysis - Frequently Asked Questions How have GRI shares performed in 2024? GRI Bio's stock was trading at 2.70 at the beginning of 2024. Since then, GRI shares have decreased by 84.4% and is now trading at 0.42. View the best growth stocks for 2024 here. When is GRI Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our GRI earnings forecast. How were GRI Bio's earnings last quarter? GRI Bio, Inc. (NASDAQ:GRI) released its earnings results on Friday, May, 10th. The company reported ($0.46) earnings per share (EPS) for the quarter. What ETF holds GRI Bio's stock? Dimensional International Small Cap Value ETF holds 2,071,221 shares of GRI stock, representing 0.37% of its portfolio. When did GRI Bio's stock split? GRI Bio shares reverse split before market open on Tuesday, January 30th 2024. The 1-7 reverse split was announced on Tuesday, January 30th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split. How do I buy shares of GRI Bio? Shares of GRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GRI) was last updated on 5/23/2024 by MarketBeat.com Staff From Our PartnersBill Clinton Backing Biden Replacement???The Freeport SocietyWrite this ticker symbol down…StocksToTradeThis could mean the end of the U.S dollar…Colonial MetalsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaElon to Transform U.S. Economy? Porter & CompanyHe Is Giving Away BitcoinCrypto Swap ProfitsThe Presidential candidate you should REALLY be worried aboutStansberry ResearchThis Apple-like Innovator is Revolutionizing HealthcareWall Street Star Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GRI Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.